| Phase 13 trials |
|
Phase 1
|
NCT05397223 |
May 2022 → Feb 2026 |
COVID-19, cytomegalovirus infection, influenza, respiratory syncytial virus infectious disease |
ModernaTX, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05105048 |
Nov 2021 → Aug 2023 |
cytomegalovirus infection |
ModernaTX, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03382405 |
Nov 2017 → Oct 2020 |
cytomegalovirus infection |
ModernaTX, Inc. |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT05575492 |
Nov 2022 → May 2026 |
cytomegalovirus infection |
ModernaTX, Inc. |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT06133010 |
Feb 2024 → Feb 2027 |
cytomegalovirus infection |
ModernaTX, Inc. |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT05683457 |
Apr 2023 → Aug 2026 overdue |
cytomegalovirus infection |
ModernaTX, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04232280 |
Jan 2020 → Jan 2023 |
cytomegalovirus infection |
ModernaTX, Inc. |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT05085366 |
Oct 2021 → Nov 2025 |
cytomegalovirus infection |
ModernaTX, Inc. |
Terminated
|
No outcome recorded
|